Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Retained Earnings: 2010-2024

Historic Retained Earnings for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$44.0 million.

  • China Pharma Holdings' Retained Earnings fell 7.47% to -$46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.0 million, marking a year-over-year decrease of 7.47%. This contributed to the annual value of -$44.0 million for FY2024, which is 12.05% down from last year.
  • Per China Pharma Holdings' latest filing, its Retained Earnings stood at -$44.0 million for FY2024, which was down 12.05% from -$39.3 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Retained Earnings registered a high of -$28.8 million during FY2020, and its lowest value of -$44.0 million during FY2024.
  • For the 3-year period, China Pharma Holdings' Retained Earnings averaged around -$39.8 million, with its median value being -$39.3 million (2023).
  • Data for China Pharma Holdings' Retained Earnings shows a maximum YoY fell of 12.32% (in 2022) over the last 5 years.
  • China Pharma Holdings' Retained Earnings (Yearly) stood at -$28.8 million in 2020, then decreased by 11.79% to -$32.2 million in 2021, then declined by 12.32% to -$36.2 million in 2022, then fell by 8.50% to -$39.3 million in 2023, then dropped by 12.05% to -$44.0 million in 2024.